TKIs are used in first-line for chronic and acute myeloid leukemia (CML and AML) with BCR/ABL overexpression as well as for gastrointestinal stromal tumors (GIST) with c-KIT mutations (Bennasroune et al., 2004). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.